Gland Pharma Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Gland Pharma share price Rs 3,061.50 (9 October 2026). Base target Rs 3,538, bull Rs 4,281, downside risk Rs 2,456. PE 44.88. 52W range Rs 1,573.60 to Rs 3,171.00.

Investors weighing a Gland Pharma target price for 2027 should start with where the stock sits today. At Rs 3,061.50 on 9 October 2026, it is 3.5% below its 52-week high of Rs 3,171.00 and 94.6% above its 52-week low of Rs 1,573.60. That range spans 102% from low to high, so the entry point matters as much as the Gland Pharma price forecast itself.

This article builds the Gland Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 3,538 base case and the Rs 4,281 bull case were reached, along with a downside risk level of Rs 2,456.

Click Here – Get Free Investment Predictions

Gland Pharma Stock Analysis: Company Overview and Key Stats

Gland Pharma (NSE: GLAND) has a market capitalisation of Rs 50,657 crore. In FY26 it reported revenue of Rs 6,747 crore and net profit of Rs 1,027 crore. The table collects the figures the Gland Pharma share price target is built on.

Metric	Value
Company	Gland Pharma
NSE Ticker	GLAND
CMP (9 October 2026)	Rs 3,061.50
52-Week High	Rs 3,171.00
52-Week Low	Rs 1,573.60
Market Cap	Rs 50,657 crore
PE Ratio (TTM)	44.88
Industry PE	37.59
Price to Book	4.89
Return on Equity	9.92%
Debt to Equity	0.03
EPS (TTM)	Rs 68.41
Dividend Yield	0.65%
12-Month Base Target	Rs 3,538
Bull Case	Rs 4,281
Downside Risk Level (not a target)	Rs 2,456

Why Is Gland Pharma Share Price Target Set at Rs 3,538 for 2027?

The base-case Gland Pharma stock target of Rs 3,538 applies a PE multiple of 44.88 to a forward EPS estimate of Rs 78.84. That EPS assumes 15.2% yearly growth, the pace from FY24 to FY26, and puts the target 15.6% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Gland Pharma Target Price: Five Years of Results

Gland Pharma grew revenue from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew more slowly, from Rs 1,212 crore to Rs 1,027 crore (-4.0% a year), which points to margin pressure alongside the sales growth.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	4,624.65	1,211.66	73.64	0.00
FY23	3,865.06	781.04	47.43	0.00
FY24	5,834.96	772.46	46.89	20.00
FY25	5,830.11	698.53	42.40	18.00
FY26	6,746.98	1,027.32	62.28	20.00

FY26 revenue growth was 15.7%, faster than the four-year average of 9.9%, and net profit moved up 47.1%. EPS rose from Rs 46.89 in FY24 to Rs 62.28 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Gland Pharma converted 15.2% of FY26 revenue into net profit, against 12.0% in FY25, within a five-year range of 12.0% to 26.2%. EBITDA margin was 28.5% in FY26 versus 25.4% in FY25.

In the June 2026 quarter, revenue was Rs 1,862 crore, up 19.1% from the same quarter a year earlier, while net profit of Rs 316.96 crore was up 47.1%. EBITDA came in at Rs 550.60 crore, up 29.5% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.03, and shareholders’ equity grew from Rs 7,158 crore in FY22 to Rs 10,358 crore in FY26. Operating cash flow in FY26 was Rs 1,031 crore against capital expenditure of Rs 494.43 crore, leaving free cash flow of Rs 536.96 crore, or 1.1% of the current market capitalisation. In FY25 free cash flow was Rs 520.56 crore.

Valuation Check for the Gland Pharma Stock Target: PE, Price to Book and ROE

At a PE of 44.88 against an industry PE of 37.59, Gland Pharma trades at a premium to its industry. Price to book is 4.89 on a book value of Rs 627.71 per share, and return on equity is 9.92%. A PE of 44.88 equals an earnings yield of 2.2%, and the FY26 dividend of Rs 20.00 per share gives a yield of 0.65%.

Shareholding Pattern and Institutional Holding

Promoters held 51.77% of Gland Pharma in June 2026, and promoter holding has stayed near 51.77% since June 2025. Foreign institutional investors (FII) held 8.74% and domestic institutions (DII) held 30.44%, which puts total institutional holding at 39.18%. FII holding rose from 7.39% in June 2025 to 8.74% in June 2026. Public shareholders own the remaining 9.05%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Gland Pharma Share Price Targets for the Short Term and 12 Months

Short Term Gland Pharma Stock Target Levels: Technical Setup

At Rs 3,061.50 on 9 October 2026, Gland Pharma trades above its 50-day simple moving average of Rs 2,864.76 and above its 200-day exponential moving average of Rs 2,365.32. The 14-day RSI reads 57.3, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 3,171.00 (52-week high) and the nearest support is Rs 2,864.76 (50-day simple moving average). A sustained move above Rs 3,171.00 would improve the short-term setup, while a close below Rs 2,864.76 would shift attention to the next support.

12 Month Gland Pharma Target Price for 2027

The 12-month target for Gland Pharma is Rs 3,538: forward EPS of Rs 78.84 at a PE of 44.88. That is 15.6% above Rs 3,061.50. It would also push the stock above its 52-week high of Rs 3,171.00.

How EPS Growth and PE Multiple Change the Gland Pharma Target Price

EPS Growth	PE 35.90	PE 44.88	PE 51.61
0.0% (EPS Rs 68.41)	Rs 2,456	Rs 3,070	Rs 3,531
15.2% (EPS Rs 78.84)	Rs 2,830	Rs 3,538	Rs 4,069
21.2% (EPS Rs 82.95)	Rs 2,978	Rs 3,723	Rs 4,281

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Gland Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Gland Pharma Stock Target in 2027

Bull Case Rs 4,281

The bull case Gland Pharma price target needs EPS growth of 21.2%, which lifts forward EPS to Rs 82.95, and a PE multiple that rises 15% to 51.61. That gives Rs 4,281, 39.8% above the current price and above the 52-week high of Rs 3,171.00, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 2,456

The downside risk level is not a target. It assumes EPS stays flat at Rs 68.41 and the PE falls 20% to 35.90. That gives Rs 2,456, 19.8% below the current price and above the 52-week low of Rs 1,573.60.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	21.2%	51.61	Rs 4,281	+39.8%
Base Case	15.2%	44.88	Rs 3,538	+15.6%
Downside Risk	0.0%	35.90	Rs 2,456	-19.8%

Key Risks to the Gland Pharma Target Price for 2027

Growth Slowdown Risk for the Gland Pharma Price Target

Revenue in the June 2026 quarter was up 19.1% year on year, and FY26 revenue growth was 15.7%. If growth slows from here, the EPS estimate behind the Gland Pharma stock target will need revising.

Liquidity and Size Risk

Gland Pharma has a market capitalisation of Rs 50,657 crore. Institutional holding is 39.18%, and promoters hold 51.77%. A company of this size trades with deep liquidity, so entry and exit are rarely a problem, and the larger risk is paying too much for slow earnings growth.

Valuation and Margin Risk

Net margin was 15.2% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 44.88 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 35.90 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 3.5% below its 52-week high, with an RSI of 57.3 and a MACD reading above its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Gland Pharma

Start with the live price and volume. Any Gland Pharma share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 3,061.50 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Gland Pharma’s PE, ROE, debt and shareholding in one place.

Check Gland Pharma fundamentals on the Univest Screener

Then compare the three Gland Pharma target price scenarios with your own view. If you expect EPS growth below 15.2%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Gland Pharma live price and get daily stock recommendations.

Conclusion

The Gland Pharma share price target for 2027 is Rs 3,538 in the base case, with Rs 4,281 as the bull case. The support for that view is arithmetic you can check: EPS grew 15.2% a year over FY24 to FY26, and the stock trades at a PE of 44.88. The risks are equally concrete, including a stock that sits 3.5% below its 52-week high and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Gland Pharma Share Price Target 2027

What is the Gland Pharma share price target for 2027?

Ans. The base-case Gland Pharma share price target for 2027 is Rs 3,538, with Rs 4,281 as the bull case. The downside risk level, which is not a target, is Rs 2,456. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Gland Pharma share price today?

Ans. As of 9 October 2026, 1:18 PM IST, Gland Pharma trades at Rs 3,061.50, down 0.57% on the day. The 52-week range is Rs 1,573.60 to Rs 3,171.00.

Is Gland Pharma a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 15.2% a year over FY24 to FY26, but the stock is 3.5% below its 52-week high. Whether Gland Pharma fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Gland Pharma shares?

Ans. The bull case target is Rs 4,281, which assumes 21.2% EPS growth and a PE of 51.61. The downside risk level is Rs 2,456, which assumes flat EPS and a PE of 35.90. It marks a risk, not a target.

What are the main risks to the Gland Pharma price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 50,657 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Gland Pharma and how does it compare with the industry?

Ans. The PE ratio of Gland Pharma is 44.88 against an industry PE of 37.59. Price to book is 4.89 and return on equity is 9.92%. The base case in the Gland Pharma price target holds this PE constant.

Who owns Gland Pharma, and what is the promoter holding?

Ans. Promoters held 51.77% of Gland Pharma in June 2026. FII held 8.74%, DII held 30.44% and the public held 9.05%.

What were Gland Pharma’s latest quarterly results?

Ans. In the June 2026 quarter, Gland Pharma reported revenue of Rs 1,862 crore (up 19.1% year on year) and net profit of Rs 316.96 crore (up 47.1%).